Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: Does ceasing therapy due to toxicity worsen outcomes in long term?

International Journal of Clinical Practice

Volumn 70, Issue 4, 2016, Pages 340-350

  Wabe, N ^a   Sorich, M J ^a,b   Wechalekar, M D ^b,c   Cleland, L G ^c,d   McWilliams, L ^c   Lee, A ^c,d   Hall, C ^c   Spargo, L ^c   Metcalf, R ^c   Proudman, S M ^c,d   Wiese, M D ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEALTH ASSESSMENT QUESTIONNAIRE; HELPLESSNESS; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SHORT FORM 36; SIDE EFFECT; THORAX PAIN; VISUAL ANALOG SCALE; VISUAL DISORDER; WEIGHT REDUCTION; ARTHRITIS, RHEUMATOID; DISEASE COURSE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOLLOW UP; INCIDENCE; MIDDLE AGED; PATIENT-REPORTED OUTCOME; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SOUTH AUSTRALIA; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SOUTH AUSTRALIA; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84960976289     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12785     Document Type: Article

References (34)

1. Amaya-Amaya J, Botello-Corzo D, Calixto OJ, et al., Usefulness of patients-reported outcomes in rheumatoid arthritis focus group. Arthritis 2012; 2012: 935187.
2. Pincus T,. Are patient questionnaire scores as "scientific" as laboratory tests for rheumatology clinical care? Bull NYU Hosp Jt Dis 2010; 68: 130-9.
3. Kalyoncu U, Dougados M, Daurès JP, Gossec L,. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2009; 68: 183-90.
4. Genovese MC, Han C, Keystone EC, et al., Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol 2012; 39: 1185-91.
5. Kekow J, Moots RJ, Emery P, et al., Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 2010; 69: 222-5.
6. Wells G, Li T, Maxwell L, Maclean R, Tugwell P,. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 2008; 67: 260-5.
7. Strand CV, Crawford B,. Longterm treatment benefits are best reflected by patient reported outcomes. J Rheumatol 2007; 34: 2317-9.
8. Grigor C, Capell H, Stirling A, et al., Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
9. Soubrier M, Lukas C, Sibilia J, et al., Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011; 70: 611-5.
10. Verstappen SM, Jacobs JW, der van Veen MJ, et al., Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
11. Aletaha D, Kapral T, Smolen J,. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 2003; 62: 482-6.
12. Wabe N, Sorich M, Wechalekar M, et al., Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. Arthritis Res Ther 2015; 17: 48.
13. Proudman SM, Keen HI, Stamp LK, et al., Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 2007; 37: 99-111.
14. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP,. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 1346-53.
15. DeVellis RF, Callahan LF,. A brief measure of helplessness in rheumatic disease: the helplessness subscale of the Rheumatology Attitudes Index. J Rheumatol 1993; 20: 866-9.
16. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
17. Australian Bureau of Statistics. 1995 National Health Survey: SF36 Population Norms, Australia. 1st edn. Canberra: ABS; 1997. p. 21.
18. Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P,. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford) 2010; 49: 1900-10.
19. Austad, Kvien C, Tore K, Till U,. Physical function, pain and fatigue are related to sleep disturbance in females with rheumatoid arthritis. Arthritis Rheum 2012; 64 (Suppl. 10): 90.
20. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GAM,. Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum 2004; 51: 578-85.
21. Oncu J, Basoglu F, Kuran B,. A comparison of impact of fatigue on cognitive, physical, and psychosocial status in patients with fibromyalgia and rheumatoid arthritis. Rheumatol Int 2013; 33: 3031-7.
22. Nagyova I, Stewart RE, Macejova Z, van Dijk JP, van den Heuvel WJ,. The impact of pain on psychological well-being in rheumatoid arthritis: the mediating effects of self-esteem and adjustment to disease. Patient Educ Couns 2005; 58: 55-62.
23. Margaretten M, Barton J, Julian L, et al., Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63: 240-6.
24. Vermeer M, Kuper HH, Moens HJ, et al., Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort. Arthritis Care Res (Hoboken) 2013; 65: 1219-26.
25. Emery P, Kosinski M, Li T, et al., Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 2006; 33: 681-9.
26. Hunter KU, Schipper M, Feng FY, et al., Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys 2013; 85: 935-40.
27. Tsai W-L, Huang T-L, Liao K-C, et al., Impact of late toxicities on quality of life for survivors of nasopharyngeal carcinoma. BMC Cancer 2014; 14: 856.
28. Singh JA, Furst DE, Bharat A, et al., 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
29. Smolen JS, Landewé R, Breedveld FC, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
30. Radner H, Smolen JS, Aletaha D,. Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 536-41.
31. Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A,. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 401-9.
32. Chorus AM, Miedema HS, Boonen A, van der Linden S,. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 2003; 62: 1178-84.
33. Whalley D, McKenna SP, de Jong Z, van der Heijde D,. Quality of life in rheumatoid arthritis. Rheumatology (Oxford) 1997; 36: 884-8.
34. Naranjo CA, Busto U, Sellers EM, et al., A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.